Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to ...

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Merck also said as much in its earnings release. While the company said it’s “reasonable to expect” that it’ll exceed the current consensus estimate of $2.76 to $2.81 a share for fiscal ...

Merck has released data and updates for several trials heading into its second quarter earnings report. Shares of the stock are now down year-to-date after turning out a positive gain in the first ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Merck doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.